Captopril and losartan for mitigation of renal injury caused by single-dose total-body irradiation

Radiation Research

Volumn 175, Issue 1, 2011, Pages 29-36

  Moulder, John E ^a   Cohen, Eric P ^a   Fish, Brian L ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; LOSARTAN POTASSIUM; UREA;

ARTICLE; BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; DISEASE COURSE; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RADIATION NEPHROPATHY; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RAT; UREA NITROGEN BLOOD LEVEL; UREMIA; WHOLE BODY RADIATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AZOTEMIA; CAPTOPRIL; HYPERTENSION; KIDNEY; LINEAR MODELS; LOSARTAN; MALE; PROTEINURIA; RADIATION INJURIES; RATS; RENAL INSUFFICIENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WHOLE-BODY IRRADIATION;

ANIMALIA; RODENTIA;

EID: 78650629415     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR2400.1     Document Type: Article

References (44)

1. C. N. Coleman, H. B. Stone, J. E. Moulder and T. C. Pellmar, Modulation of radiation injury. Science 304, 693-694 (2004).
2. H. B. Stone, J. E. Moulder, C. N. Coleman, K. K. Ang, M. S. Anscher, M. H. Barcellos-Hoff, W. S. Dynan, J. R. Fike, D. J. Grdina and D. Zaharevitz, Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI workshop, December 3-4, 2003. Radiat. Res. 162, 711-728 (2004).
3. J. E. Moulder, B. L. Fish and E. P. Cohen, ACE inhibitors and AII receptor antagonists in the treatment and prevention of bone marrow transplant nephropathy. Curr. Pharm. Design 9, 737-749 (2003).
4. E. P. Cohen, M. M. Joines and J. E. Moulder, Prevention and treatment of radiation injuries - The role of the renin-angiotensin system. In Late Effects of Cancer Treatment on Normal Tissues (P. Rubin, L. S. Constine, L. B. Mark and P. Okunieff, Eds.), pp. 69-76. Springer-Verlag, Heidelberg, 2008.
5. P. K. S. Siegl, R. S. L. Chang, N. B. Mantlo, P. K. Chakavarty, D. L. Ondeyka, W. J. Greenlee, A. A. Patchett, C. S. Sweet and V. J. Lotti, In vivo pharmacology of L-158,809, a highly potent and selective non-peptide angiotensin II receptor blocker. J. Pharmacol. Exp. Ther. 262, 139-144 (1992).
6. Food and Drug Administration, New drug and biological drug products: evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Fed. Regist. 67, 37988-37998 (2002).
7. J. P. Williams, S. L. Brown, G. E. Georges, A. K. Huser, R. P. Hill, M. Hauer-Jensen, D. G. Kirsch, T. J. MacVittie, K. A. Mason and W. H. McBride, Animal models for medical countermeasures. Radiat. Res. 173, 557-578 (2010).
8. J. E. Moulder and B. L. Fish, Late toxicity of total body irradiation with bone marrow transplantation in a rat model. Int. J. Radiat. Oncol. Biol. Phys. 16, 1501-1509 (1989).
9. E. P. Cohen, B. L. Fish and J. E. Moulder, The renin-angiotensin system in experimental radiation nephropathy. J. Lab. Clin. Med. 139, 251-257 (2002).
10. E. P. Cohen, B. L. Fish, M. Sharma, X. A. Li and J. E. Moulder, Role of the angiotensin II type-2 receptor in radiation nephropathy. Transl. Res. 150, 106-115 (2007).
11. E. P. Cohen, B. L. Fish and J. E. Moulder, Successful brief captopril treatment in radiation nephropathy. J. Lab. Clin. Med. 129, 536-547 (1997).
12. J. E. Moulder, B. L. Fish and E. P. Cohen, Brief pharmacologic intervention in experimental radiation nephropathy. Radiat. Res. 150, 535-541 (1998).
13. E. P. Cohen, A. A. Irving, W. R. Drobyski, J. P. Klein, J. Passweg, J. Talano, M. Juckett and J. E. Moulder, Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. Int. J. Radiat. Oncol. Biol. Phys. 70, 1546-1551 (2008).
14. E. P. Cohen, J. E. Moulder, B. L. Fish and P. Hill, Prophylaxis of experimental bone marrow transplant nephropathy. J. Lab. Clin. Med. 124, 371-380 (1994).
15. K. A. Brownlee, Simple linear regression. In Statistical Theory and Methodology in Science and Engineering, 2nd ed., pp. 605- 611. Wiley, New York, 1965.
16. J. E. Moulder and S. Rockwell, Hypoxic fractions of solid tumors: Experimental techniques, methods of analysis, and a survey of existing data. Int. J. Radiat. Oncol. Biol. Phys. 10, 695-712 (1984).
17. A. M. Kellerer and J. Brenot, Nonparametric determination of modifying factors in radiation action. Radiat. Res. 56, 28-39 (1973).
18. D. J. Finney, Statistical Methods in Biological Assay. Macmillan, New York, 1978.
19. J. E. Moulder, B. L. Fish, K. R. Regner and E. P. Cohen, Angiotensin II blockade reduces radiation-induced proliferation in experimental radiation nephropathy. Radiat. Res. 157, 393-401 (2002).
20. J. E. Moulder, B. L. Fish and E. P. Cohen, Dietary sodium modification and experimental radiation nephropathy. Int. J. Radiat. Biol. 79, 903-911 (2002).
21. E. P. Cohen, A. Molteni, P. Hill, B. L. Fish, W. F. Ward, J. E. Moulder and F. A. Carone, Captopril preserves function and ultrastructure in experimental radiation nephropathy. Lab. Invest. 75, 349-360 (1996).
22. J. E. Moulder, B. L. Fish and E. P. Cohen, Treatment of radiation nephropathy with ACE inhibitors and AII type-1 and type-2 receptor antagonists. Curr. Pharm. Design 13, 1317-1325 (2007).
23. W. McFate Smith, R. O. Davies, M. A. Gabriel, D. M. Kramsch, F. Moncloa, J. E. Rush and J. F. Walker, Tolerance and safety of enalapril. Br. J. Clin. Pharmacol. 18 (Suppl. 2), 249S-253S (1984).
24. E. J. Lewis, L. G. Hunsicker, R. P. Bain and R. D. Rohde, The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329, 1456-1462 (1993).
25. F. Rengo, D. Acanfora, G. Furgi, A. Papa, A. Nicolino, C. Picone, D. F. Vitale and C. Rengo, Comparison of the safety and efficacy of delapril with enalapril in patients with congestive heart failure. Am. J. Cardiol. 75, 25F-28F (1995).
26. J. Mason, P. Young, N. Freemantle and R. Hobbs, Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction. BMJ 321, 1113-1116 (2000).
27. RTOG-0123: A Phase II randomized trial with captopril in patients who have received radiation therapy±chemotherapy for stage II-IIIB non-small cell lung cancer, stage I central non-small cell lung cancer, or limited-stage small cell lung cancer. Radiation Therapy Oncology Group, Philadelphia, 2004.
28. A Phase II Randomized Trial with Captopril in Patients Who Have Received Radiation Therapy z/2 Chemotherapy for Stage II-IIIB Non-Small Cell Lung Cancer, Stage I Central Non-Small Cell Lung Cancer, or Limited-Stage Small-Cell Lung Cancer (Report June 2009). Radiation Therapy Oncology Group, Philadelphia, 2009.
29. J. E. Moulder, B. L. Fish, E. P. Cohen and S. M. Bonsib, Angiotensin II receptor antagonists in the prevention of radiation nephropathy. Radiat. Res. 146, 106-110 (1996).
30. G. Bönner, W. Smolka, C. Jung and K. Bestehorn, Efficacy and safety of losartan 100 mg or losartan 100 mg plus hydrochlorothiazide 25 mg in the treatment of patients with essential arterial hypertension and CV risk factors: observational, prospective study in primary care. Curr. Med. Res. Opin. 25, 981-990 (2009).
31. G. T. McInnes, Clinical advantage of valsartan. Cardiology 91 (Suppl. 1), 14-18 (1999).
32. A. Molteni, J. E. Moulder, E. P. Cohen, B. L. Fish, J. M. Taylor, P. A. Veno, L. F. Wolfe and W. F. Ward, Prevention of radiation-induced nephropathy and fibrosis in a model of bone marrow transplant by an angiotensin II receptor blocker. Exp. Biol. Med. 226, 1016-1023 (2001).
33. E. P. Cohen, B. L. Fish and J. E. Moulder, Mitigation of radiation injuries via suppression of the renin-angiotensin system: Emphasis on radiation nephropathy. Curr. Drug Targets 11, 1423-1429 (2010).
34. E. P. Cohen, C. A. Lawton and J. E. Moulder, Bone marrow transplant nephropathy: Radiation nephritis revisited. Nephron 70, 217-222 (1995).
35. E. P. Cohen and M. E. C. Robbins, Radiation nephropathy. Semin. Nephrol. 23, 486-499 (2003).
36. C. Antignac, M. C. Gubler, G. Leverger, M. Broyer and R. Habib, Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney Int. 35, 1336-1344 (1989).
37. H. B. Kal and M. L. van Kempen-Harteveld, Renal dysfunction after total body irradiation: Dose-effect relationship: In regard to Kal and Van Kempen-Harteveld (Int J Radiat Oncol Biol Phys 2006; 65: 1228-1232) - In reply to Drs. Moulder and Cohen. Int. J. Radiat. Oncol. Biol. Phys. 67, 319-320 (2007).
38. E. P. Cohen, B. L. Fish and J. E. Moulder, Angiotensin II infusion exacerbates radiation nephropathy. J. Lab. Clin. Med. 134, 283-291 (1999).
39. J. E. Moulder, M. E. C. Robbins, E. P. Cohen, J. W. Hopewell and W. F. Ward, Pharmacologic modification of radiation-induced late normal tissue injury. Cancer Treat. Res. 93, 129-151 (1998).
40. M. Lenfant, K. Itoh, H. Sakoda, D. Sotty, N. A. Sasaki, J. Wdzieczak-Bakala and K. J. Mori, Enhancement of the adherence of hematopoietic stem cells to mouse bone marrow-derived stromal cell line MS-1-T by a tetrapeptide acetyl-N-Ser-Asp-Lys-Pro. Exp. Hematol. 17, 898-902 (1989).
41. M. Azizi, E. Ezan, L. Nicolet, J. M. Grognet and J. Menard, High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 30, 1015-1019 (1997).
42. H. Peng, O. A. Carretero, D. R. Brigstock, N. Oja-Tebbe and N. E. Rhaleb, Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension. Hypertension 42, 1164-1170 (2003).
43. N. Iwamoto, H. J. Xano, T. Yoshioka, H. Shiraga, K. Nitta, T. Muraki and K. Ito, Acetyl-seryl-aspartyl-lysyl-proline is a novel natural cell cycle regulator of renal cells. Life Sci. 66, 221-226 (2000).
44. M. Azizi, A. Rousseau, E. Ezan, T. Guyene, T., S. Michelet, J. M. Grognet, M. Lenfant, P. Corvol and J. Menard, Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J. Clin. Invest. 97, 839-844 (1996).